Biopharma AI
By
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and Rare Diseases in 2026?
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to strengthen its pipeline,…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in 2026?
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for the Future?
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…
What Lessons from Sanofi’s 2025 Execution Signal Its Future in Oncology, Immunology, and Vaccines?
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
Are AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…
